Please login to the form below

Not currently logged in
Email:
Password:

Dementia Discovery Fund

This page shows the latest Dementia Discovery Fund news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: DDF hits £250m investment, Hard Brexit could cost UK £100bn in trade and troublesome results for Pfizer’s Ibrance

Daily Brief: DDF hits £250m investment, Hard Brexit could cost UK £100bn in trade and troublesome results for Pfizer’s Ibrance

The Dementia Discovery Fund (DDF) confirmed yesterday that it had raised £250m ($350m), boosted by a $60m investment from US non-profit organisation AARP aimed at helping older people live healthier ... lives. The fundraising far exceeded its initial

Latest news

  • British Business Bank sets up £2.5bn fund for ‘unicorn’ firms British Business Bank sets up £2.5bn fund for ‘unicorn’ firms

    A new UK government-backed investment vehicle to provide long-term capital for British businesses has been launched, with a fund backing dementia drug developers among the first to benefit. ... The Dementia Discovery Fund is one of two VCs given funding

  • Pfizer drops neuroscience R&D, cutting 300 jobs Pfizer drops neuroscience R&D, cutting 300 jobs

    It will also set up a dedicated venture capital fund to invest in other companies carrying out neuroscience R&D and “support continued efforts to advance the field”. ... Pfizer is already one of the founder members of the cross-company Dementia

  • Woodford investment pushes Dementia Discovery Fund to £100m Woodford investment pushes Dementia Discovery Fund to £100m

    Woodford investment pushes Dementia Discovery Fund to £100m. Fund aims to back 40 projects over its 15-year term. ... Thanks to a £15m pledge from Neil Woodford's investment group, the public-private Dementia Discovery Fund (DDF) has now raised close

  • GSK and J&J back new UK dementia discovery fund GSK and J&J back new UK dementia discovery fund

    GSK and J&J back new UK dementia discovery fund. Pharma giants collaborate with government to find new treatments. ... GlaxoSmithKline, Johnson &Johnson and Pfizer have signed up to support a new UK government dementia discovery fund.

  • Freeman: More pharma-charity research partnerships needed Freeman: More pharma-charity research partnerships needed

    Similar partnerships have been launched in recent years for conditions, including dementia and Parkinson's disease - both areas of significant unmet medical need. ... Earlier this year, Lilly, Pfizer, GlaxoSmithKline, Biogen Idec and Johnson &Johnson

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2)

    and GlaxoSmithKline have each signed significant strategic discovery deals during Eva-Lotta’s five years at Immunocore. ... the UK’s new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee.

  • The world is our laboratory The world is our laboratory

    This year, through J&J Innovation, we will invest $10m into the UK government-led Global Dementia Discovery Fund, supporting innovative research into the area. ... This was set up in 2013 to identify innovative solutions for dementia care.

  • Pharma deals in March 2015 Pharma deals in March 2015

    This month saw GSK invest $25m, J&J $10m and the UK Government $22m into the Dementia Discovery fund, a joint initiative also including Lilly, Biogen and Pfizer to research treatments

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Forecasting in Forgotten Markets

    To help address a lack of investment in novel dementia science a new £100M Dementia Discovery Fund ( ) was launched towards the end of last year. ... Managed by SV Life Sciences the fund is focused primarily on Phase I and II research and aims to help

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics